Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24‑month extension safety study of ranibizumab (Lucentis) after RESTORE in diabetic macular edema
2008-007467-17Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Started Apr 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2008-007467-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007467-17.